Gibson Elizabeth A, Li Huichu, Fruh Victoria, Gabra Malaika, Asokan Gowtham, Jukic Anne Marie Z, Baird Donna D, Curry Christine L, Fischer-Colbrie Tyler, Onnela Jukka-Pekka, Williams Michelle A, Hauser Russ, Coull Brent A, Mahalingaiah Shruthi
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA.
Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA.
medRxiv. 2022 Jul 10:2022.07.07.22277371. doi: 10.1101/2022.07.07.22277371.
COVID-19 vaccination may be associated with change in menstrual cycle length following vaccination.
We conducted a longitudinal analysis within a subgroup of 14,915 participants in the Apple Women's Health Study (AWHS) who enrolled between November 2019 and December 2021 and met the following eligibility criteria: were living in the U.S., met minimum age requirements for consent, were English speaking, actively tracked their menstrual cycles, and responded to the COVID-19 Vaccine Update survey. In the main analysis, we included tracked cycles recorded when premenopausal participants were not pregnant, lactating, or using hormonal contraceptives. We used conditional linear regression and multivariable linear mixed-effects models with random intercepts to estimate the covariate-adjusted difference in mean cycle length, measured in days, between pre-vaccination cycles, cycles in which a vaccine was administered, and post-vaccination cycles within vaccinated participants, and between vaccinated and unvaccinated participants. We further compared associations between vaccination and menstrual cycle length by the timing of vaccine dose within a menstrual cycle (i.e., in follicular or luteal phase). We present Bonferroni-adjusted 95% confidence intervals to account for multiple comparisons.
A total of 128,094 cycles (median = 10 cycles per participant; interquartile range: 4-22) from 9,652 participants (8,486 vaccinated; 1,166 unvaccinated) were included. The average within-individual standard deviation in cycle length was 4.2 days. Fifty-five percent of vaccinated participants received Pfizer-BioNTech's mRNA vaccine, 37% received Moderna's mRNA vaccine, and 7% received the Johnson & Johnson/Janssen vaccine (J&J). We found no evidence of a difference between mean menstrual cycle length in the unvaccinated and vaccinated participants prior to vaccination (0.24 days, 95% CI: -0.34, 0.82).Among vaccinated participants, COVID-19 vaccination was associated with a small increase in mean cycle length (MCL) for cycles in which participants received the first dose (0.50 days, 95% CI: 0.22, 0.78) and cycles in which participants received the second dose (0.39 days, 95% CI: 0.11, 0.67) of mRNA vaccines compared with pre-vaccination cycles. Cycles in which the single dose of J&J was administered were, on average, 1.26 days longer (95% CI: 0.45, 2.07) than pre-vaccination cycles. Post-vaccination cycles returned to average pre-vaccination length. Estimates for pre vs post cycle lengths were 0.14 days (95% CI: -0.13, 0.40) in the first cycle following vaccination, 0.13 days (95% CI: -0.14, 0.40) in the second, -0.17 days (95% CI: -0.43, 0.10) in the third, and -0.25 days (95% CI: -0.52, 0.01) in the fourth cycle post-vaccination. Follicular phase vaccination was associated with an increase in MCL in cycles in which participants received the first dose (0.97 days, 95% CI: 0.53, 1.42) or the second dose (1.43 days, 95% CI: 1.06, 1.80) of mRNA vaccines or the J&J dose (2.27 days, 95% CI: 1.04, 3.50), compared with pre-vaccination cycles.
COVID-19 vaccination was associated with an immediate short-term increase in menstrual cycle length overall, which appeared to be driven by doses received in the follicular phase. However, the magnitude of this increase was small and diminished in each cycle following vaccination. No association with cycle length persisted over time. The magnitude of change associated with vaccination was well within the natural variability in the study population. Menstrual cycle change following COVID-19 vaccination appears small and temporary and should not discourage individuals from becoming vaccinated.
接种新冠病毒疫苗(COVID-19疫苗)可能与接种后月经周期长度的变化有关。
我们在苹果女性健康研究(AWHS)的14915名参与者的子集中进行了一项纵向分析,这些参与者在2019年11月至2021年12月期间入组,并符合以下资格标准:居住在美国,达到同意参与的最低年龄要求,说英语,积极记录其月经周期,并对COVID-19疫苗更新调查做出回应。在主要分析中,我们纳入了绝经前参与者在未怀孕、未哺乳或未使用激素避孕措施时记录的月经周期。我们使用条件线性回归和具有随机截距的多变量线性混合效应模型,以估计接种疫苗前的周期、接种疫苗的周期和接种疫苗参与者接种后的周期之间,以及接种疫苗和未接种疫苗的参与者之间,经协变量调整后的平均周期长度差异(以天为单位)。我们还根据月经周期内疫苗接种的时间(即卵泡期或黄体期)比较了疫苗接种与月经周期长度之间的关联。我们给出了经邦费罗尼校正的95%置信区间,以考虑多重比较。
共纳入了9652名参与者(8486名接种疫苗者;1166名未接种疫苗者)的128094个周期(中位数=每位参与者10个周期;四分位间距:4-22)。周期长度的个体内平均标准差为4.2天。55%的接种疫苗参与者接受了辉瑞-生物科技公司的mRNA疫苗,37%接受了莫德纳公司的mRNA疫苗,7%接受了强生/杨森疫苗(J&J)。我们发现,在接种疫苗前,未接种疫苗和接种疫苗的参与者的平均月经周期长度之间没有差异(0.24天,95%置信区间:-0.34,0.82)。在接种疫苗的参与者中,与接种疫苗前的周期相比,参与者接受第一剂mRNA疫苗的周期(0.50天,95%置信区间:0.22,0.78)和接受第二剂mRNA疫苗的周期(0.39天,95%置信区间:0.11,0.67)的平均周期长度有小幅增加。接种单剂J&J疫苗的周期平均比接种疫苗前的周期长1.26天(95%置信区间:0.45,2.07)。接种疫苗后的周期恢复到接种疫苗前的平均长度。接种疫苗后的第一个周期中,接种前与接种后周期长度的估计差异为0.14天(95%置信区间:-0.13,0.40),第二个周期为0.13天(95%置信区间:-0.14,0.40),第三个周期为-0.17天(95%置信区间:-0.43,0.10),第四个周期为-0.25天(95%置信区间:-0.52,0.01)。与接种疫苗前的周期相比,卵泡期接种疫苗与参与者接受第一剂(0.97天,95%置信区间:0.53,1.42)或第二剂(1.43天,95%置信区间:1.06,1.80)mRNA疫苗或J&J疫苗剂量(2.27天,95%置信区间:1.04,3.50)的周期中平均周期长度增加有关。
接种COVID-19疫苗总体上与月经周期长度立即出现短期增加有关,这似乎是由卵泡期接种的剂量所驱动。然而,这种增加的幅度较小,且在接种后的每个周期中逐渐减小。随着时间的推移,与周期长度没有持续关联。与接种疫苗相关的变化幅度完全在研究人群的自然变异性范围内。COVID-19疫苗接种后月经周期的变化似乎很小且是暂时的,不应阻碍个人接种疫苗。